Fdc-aim-χ1: A first-in-class, programmable functional drug complex for targeted cardio-renal protection

FDC-AIM-χ1 is a first-in-class, programmable Functional Drug Complex (FDC) engineered to address chronic inflammatory and metabolic stress in cardio-renal tissues. Designed via the deterministic Moleculogic framework, this therapeutic system bypasses the systemic toxicities of legacy drugs by utilizing a dually-gated sequential logic loop. Under healthy physiological conditions (pH 7.4), the macromolecular carrier remains fully shielded and inert. Upon entering ischemic, hypoxic, or inflamed microenvironments, a localized logic gate (AND/SEQ: pH < 6.5 and ROS > 50 uM) triggers conformational destabilization of the linker, releasing the active cardiotonic and anti-inflammatory payload strictly within the targeted damaged tissues.

Pre-synthesis proof to date has been established through exhaustive validation inside the SEI (Synthetic Evolving Intelligence) simulation environment. The active complex achieved a verified binding free energy of -11.38 kcal/mol (representing a low-nanomolar Kd of approximately 4.5 nM), stabilized by 3 hydrogen bonds and 10 hydrophobic contacts. Parallel ADMET profiling models hERG channel blockage and hepatotoxicity risk as negligible (<15%), and the underlying logic is cryptographically anchored to the ExergyNet L0 ledger (LNES-04 Base/Solana) for absolute, unforgeable data integrity. Next steps involve partnering with strategic biopharma and Contract Research Organizations (CROs) to execute physical wet-lab validation (in vitro Caco-2 permeability and in vivo PK/PD profiling) using our pre-compiled, automated experimental protocol cards.